Vaccines and Global Health: The Week in Review :: 11 July 2020

Independent evaluation of global COVID-19 response announced – WHO

Milestones :: Perspectives :: Research

 

Independent evaluation of global COVID-19 response announced – WHO
9 July 2020 News release Geneva, Switzerland
WHO Director-General today announced the initiation of the Independent Panel for Pandemic Preparedness and Response (IPPR) to evaluate the world’s response to the COVID-19 pandemic.

In remarks to WHO Member States, Director-General Tedros Adhanom Ghebreyesus said the Panel will be co-chaired by former Prime Minister of New Zealand Helen Clark and former President of Liberia Ellen Johnson Sirleaf. Prime Minister Clark went to on lead the United Nations Development Programme and President Sirleaf is a recipient of the Nobel Peace Prize.

Operating independently, they will choose other Panel members as well as members of an independent secretariat to provide support.

“Prime Minister Clark and President Sirleaf were selected through a process of broad consultation with Member States and world experts. I cannot imagine two more strong-minded, independent leaders to help guide us through this critical learning process.” said Dr. Tedros in his speech.

At the historic 73rd World Health Assembly in May, Member States adopted a landmark resolution that called on WHO to initiate an independent and comprehensive evaluation of the lessons learned from the international health response to COVID-19.

“This is a time for self-reflection, to look at the world we live in and to find ways to strengthen our collaboration as we work together to save lives and bring this pandemic under control,” said Dr Tedros. “The magnitude of this pandemic, which has touched virtually everyone in the world, clearly deserves a commensurate evaluation.”

Dr Tedros proposed that a Special Session of the Executive Board be called in September to discuss the Panel’s progress. In November the Panel will present an interim report at the resumption of the World Health Assembly.

In January 2021, the Executive Board will hold its regular session, where the Panel’s work will be further discussed; and in May of next year, at the World Health Assembly, the panel will present its substantive report.

The Director-General noted that the Independent Oversight and Advisory Committee for the WHO Health Emergencies Programme will also continue its existing work.

“Even as we fight this pandemic, we must be readying ourselves for future global outbreaks and the many other challenges of our time such as antimicrobial resistance, inequality and the climate crisis,” said Dr Tedros. “COVID-19 has taken so much from us. But it is also giving us an opportunity to break with the past and build back better.”

WHO experts to travel to China

Milestones :: Perspectives :: Research

 

WHO experts to travel to China
7 July 2020 Statement
WHO experts will travel to China to work together with their Chinese counterparts to prepare scientific plans for identifying the zoonotic source of the SARS-COV-2 virus. The experts will develop the scope and TOR for a WHO-led international mission.
Identifying the origin of emerging viral disease has proven complex in past epidemics in different countries. A well planned series of scientific researches will advance the understanding of animal reservoirs and the route of transmission to humans. The process is an evolving endeavor which may lead to further international scientific research and collaboration globally.

COVID-19: the worst may be yet to come

Milestones :: Perspectives :: Research

 

The Lancet
Jul 11, 2020, Volume 396 Number 10244 p71-142, e1
https://www.thelancet.com/journals/lancet/issue/current
Editorial
COVID-19: the worst may be yet to come
The Lancet
As much of western Europe begins to ease countrywide lockdowns, globally the pandemic may still be in its infancy, with more than 160 000 new cases reported each day since June 25. Individual countries count cases differently, so direct comparisons are difficult, but the numbers illustrate a worrying pattern. At a subnational level the picture is nuanced, with local hotspots, but at a country level the picture is clear—the world is facing a worsening multipolar pandemic.

The USA, Brazil, and India each logged more than 100 000 new cases from June 26 to July 3. But the pandemic also rages in Russia, forming a belt of infection that tracks through central Asia and into the Middle East and the Indian subcontinent. Increasing COVID-19 cases in South Africa mean that the pandemic has a strong foothold in sub-Saharan Africa, which is particularly alarming as parts of Africa consider resuming internal air travel later this month. Despite President Trump’s July 4 claims that “99% of cases are harmless” and of a “strategy that is moving along well”, the USA has the most new cases worldwide—53 213 on July 4, and a total of 128 481 deaths, almost a quarter of the total deaths globally. These beacons of infection show the fragility of any progress.

During the first days of July, 2020, Kazakhstan recorded the second highest number of new cases within Europe after Russia. Reporting in the largely authoritarian central Asian states has been unreliable. Turkmenistan has yet to report a single case of COVID-19 and Tajikistan has yet to provide breakdowns to WHO. Regardless, the health and economic outlook for the region is bleak. These countries have some of the highest ratios of out-of-pocket health-care spending to total health expenditure in the world, with women in particular having very poor access to health care, further obscuring the true numbers of COVID-19 cases. At the beginning of the pandemic, 2·7 million to 4·2 million central Asian labour migrant workers were estimated to be residing in Russia. Many remain stranded in areas with a high infection risk, meaning reintroduction of the virus might become a problem after the initial wave.

At the end of June, the Eastern Mediterranean region reached 1 million cases of COVID-19. Iran, Pakistan, and Saudi Arabia continue to report the highest number of infections. Most countries grapple with the challenging balance of suppressing the virus while trying to prevent the estimated 66% of the population who are either classified as poor or vulnerable to poverty being pushed into further destitution. The Gulf states are outliers. Saudi Arabia has implemented an essentially unlimited budget, expanding intensive care unit bed capacity and opening hundreds of so-called fever clinics to allow free access for patients with symptoms, and health-care workers are being retrained virtually. Meanwhile, neighbouring Iraq is struggling with oxygen shortages and Yemen faces the human catastrophe of COVID-19 in an unstable conflict zone.

In India, after relaxation of a 3-month lockdown, cases are surging. Maharashtra, Delhi, and Gujarat are among the worst hit states, with the army needed to help overwhelmed health-care centres. But some of the larger Indian states have yet to witness a substantial rise in COVID-19 cases, so the country is braced for further rapid transmission of the virus. Unfortunately, although the lockdown bought time, it was not used effectively to increase capacity in the health-care system in India. There has not been a systematic restructuring of medical provision or redeployment of health-care staff. With less than eight doctors per 10 000 population, using these resources efficiently will be crucial in the coming months.

In Central and South America, Brazil steals the headlines for the highest number of COVID-19 cases, but Mexico, Columbia, Peru, Chile, and Argentina also have cases in the thousands, forming a clear pattern of transmission across Latin America. A letter published in The Lancet describes the Pan American Health Organization as on the brink of closure because of member states’ non-payment. Never has a coordinating regional health body been more important.

Two seroprevalence studies from Spain and Geneva published in The Lancet reveal an estimated seroprevalence of 5% nationally (10% in urban areas) and 10·8%, respectively. Even if antibodies confer immunity, most of the global population remains susceptible to SARS-CoV-2. 5 months after WHO declared the SARS-CoV-2 outbreak a global health emergency, the virus continues to beat a concerning and complex path. For much of the globe, the worst may be yet to come.

EMERGENCIES: Coronavirus [COVID-19]

EMERGENCIES

 

Coronavirus [COVID-19]
Public Health Emergency of International Concern (PHEIC)

WHO – Situation report – 173
Coronavirus disease 2019 (COVID-19)
11 July 2020

Confirmed cases :: 12 322 395
Confirmed deaths :: 556 335

 

Highlights
:: Yesterday, WHO launched the Access Initiative for Quitting Tobacco, which aims to help the world’s 1.3 billion tobacco users quit during the pandemic. Smoking kills eight million people a year and smokers are more vulnerable to developing a severe case of COVID-19. WHO received its first-ever donation of nicotine replacement therapies for the project from Johnson & Johnson Consumer Health. The Initiative also enlists the help of WHO’s – and the world’s – first ever virtual health worker, Florence. You can speak with Florence, to dispel myths around COVID-19 and smoking, and to help develop a personalized plan to quit tobacco. WHO is in the final stages of adding more partners and encourages pharmaceutical and technology companies to join this initiative.

:: WHO has published guidance on maintaining a safe and adequate blood supply during the coronavirus disease pandemic.

:: Last Thursday WHO Director-General Dr Tedros announced the establishment of the Independent panel for Pandemic Preparedness and Response (IPPR) to evaluate the world’s response to the COVID-19 pandemic. “This is a time for self-reflection, to look at the world we live in and to find ways to strengthen our collaboration as we work together to save lives and bring this pandemic under control” said Dr Tedros.

 

::::::

Moderna Completes Enrollment of Phase 2 Study of its mRNA Vaccine Against COVID-19 (mRNA-1273)
:: Cohorts of younger adults (n=300) and older adults (n=300) in Phase 2 study fully enrolled
:: Cohorts of older adults (ages 56-70, n=30) and elderly adults (ages 71 and above, n=30) in NIH-led Phase 1 study completed enrollment; results expected to be published once available
:: Pivotal Phase 3 study expected to begin in July; manufacture of vaccine required to start Phase 3 study completed
July 08, 2020

 

::::::
::::::

Emergencies

Emergencies

POLIO
Public Health Emergency of International Concern (PHEIC)

Editor’s Note:
The regular “Polio: This Week” report was not active on the Global Polio Eradication Initiative website.

06/07/2020
Polio eradication expertise backs Africa’s COVID-19 response
Significant polio programme resources are being used to fight the pandemic.

 

::::::
::::::

WHO Grade 3 Emergencies [to 11 July 2020]

Democratic Republic of the Congo
:: Ebola Outbreak in DRC 98: 23 June 2020 [latest/?last Ebola Situation Report]

Mozambique floods – No new digest announcements identified
Nigeria – No new digest announcements identified
Somalia – No new digest announcements identified
South Sudan – No new digest announcements identified
Syrian Arab Republic – No new digest announcements identified
Yemen – No new digest announcements identified

 

::::::

WHO Grade 2 Emergencies [to 11 July 2020]
Burkina Faso [in French]
:: Riposte au Covid-19 : des influenceurs, blogueurs et activistes mis à contribution à…
07 juillet 2020
:: Le Burkina Faso reprend les campagnes de vaccination contre la polio en appliquant d…
06 juillet 2020

Angola – No new digest announcements identified
Afghanistan – No new digest announcements identified
Burundi – No new digest announcements identified
Cameroon – No new digest announcements identified
Central African Republic – No new digest announcements identified
Ethiopia – No new digest announcements identified
Iraq – No new digest announcements identified
Libya – No new digest announcements identified
Malawi – No new digest announcements identified
Measles in Europe – No new digest announcements identified
MERS-CoV – No new digest announcements identified
Myanmar – No new digest announcements identified
Niger – No new digest announcements identified
occupied Palestinian territory – No new digest announcements identified
HIV in Pakistan
Sao Tome and Principe Necrotizing Cellulitis (2017)
Sudan – No new digest announcements identified
Ukraine – No new digest announcements identified
Zimbabwe – No new digest announcements identified

 

::::::

WHO Grade 1 Emergencies [to 11 July 2020]

Chad – No new digest announcements identified
Djibouti – Page not responding at inquiry
Kenya – No new digest announcements identified
Mali – No new digest announcements identified
Namibia – viral hepatitis – No new digest announcements identified
Tanzania – No new digest announcements identified

 

::::::
::::::

UN OCHA – L3 Emergencies
The UN and its humanitarian partners are currently responding to three ‘L3’ emergencies. This is the global humanitarian system’s classification for the response to the most severe, large-scale humanitarian crises. 
Syrian Arab Republic
:: Syrian Arab Republic: COID-19 Update No. 14 – 10 July 2020
HIGHLIGHTS
:: Number of people confirmed by the Ministry of Health (MoH) to have COVID-19: 394 (16 fatalities, 126 recovered).
:: Areas of concern: Densely populated areas, notably Damascus/Rural Damascus, Aleppo and Homs, and those living in camps and informal settlements in NES, collective shelters throughout the country, as well as other areas including Deir-Ez-Zor, and where hostilities may be ongoing making sample collection more challenging.
:: Populations of concern: All groups are susceptible to the virus. However, the elderly (those 60 years and above) and people with underlying health conditions are particularly at risk; as are vulnerable refugee and IDP populations and healthcare workers with inadequate personal protective equipment (PPE).
:: As of 8 July, approximately 9,331 COVID-19 tests have been performed in laboratories in Damascus, Aleppo, Homs and Lattakia governorates.
:: Socio-economic impacts of COVID-19, notably in food security and livelihoods, are likely to exacerbate existing substantial humanitarian needs across the country.
:: Syrian Arab Republic: COVID-19 Response Update No. 07 – 5 July 2020

Yemen – No new digest announcements identified

 

::::::

UN OCHA – Corporate Emergencies
When the USG/ERC declares a Corporate Emergency Response, all OCHA offices, branches and sections provide their full support to response activities both at HQ and in the field.
East Africa Locust Infestation
:: Desert Locust situation update – 3 July 2020
The unprecedented Desert Locust threat to food security and livelihoods persists in the Horn of Africa and is increasing in southwest Asia.
In the Horn of Africa, second-generation spring swarms are present in northwest Kenya, eastern Ethiopia, and parts of Somalia. Breeding continues in eastern and northern Ethiopia and in central and northern Somalia where hopper bands are present. Most of the swarms in northwest Kenya will migrate northwards and cross South Sudan to Sudan while other swarms will migrate to Ethiopia. A few swarms could transit northeast Uganda. Swarms that concentrate in northern Somalia are likely to move east to the Indo-Pakistan summer breeding areas…

 

COVID-19
:: Coronavirus disease 2019 (COVID-19) Situation Report 35: occupied Palestinian territory, issued 9 July 2020, information for period: 5 March – 9 July 2020

 

::::::
::::::

WHO & Regional Offices [to 11 July 2020]

WHO & Regional Offices [to 11 July 2020]

9 July 2020 News release
Independent evaluation of global COVID-19 response announced
[See Milestones above for detail]

6 July 2020 News release
WHO: access to HIV medicines severely impacted by COVID-19 as AIDS response stalls
Countries seek innovative ways to mitigate the impact of disruptions and keep services going
Seventy-three countries have warned that they are at risk of stock-outs of antiretroviral (ARV) medicines as a result of the COVID-19 pandemic, according to a new WHO survey conducted ahead of the International AIDS Society’s biannual conference. Twenty-four countries reported having either a critically low stock of ARVs or disruptions in the supply of these life-saving medicines.
The survey follows a modelling exercise convened by WHO and UNAIDS in May which forecasted that a six-month disruption in access to ARVs could lead to a doubling in AIDS-related deaths in sub-Saharan Africa in 2020 alone.
In 2019, an estimated 8.3 million people were benefiting from ARVs in the 24 countries now experiencing supply shortages. This represents about one third (33%) of all people taking HIV treatment globally.  While there is no cure for HIV, ARVs can control the virus and prevent onward sexual transmission to other people.
A failure of suppliers to deliver ARVs on time and a shut-down of land and air transport services, coupled with limited access to health services within countries as a result of the pandemic, were among the causes cited for the disruptions in the survey.
The findings of this survey are deeply concerning,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “Countries and their development partners must do all they can to ensure that people who need HIV treatment continue to access it. We cannot let the COVID-19 pandemic undo the hard-won gains in the global response to this disease…

 

::::::

Weekly Epidemiological Record, 10 July 2020, vol. 95, 28 (pp. 325–336)
Global Advisory Committee on Vaccine Safety, 27–28 May 2020

 

::::::

WHO Regional Offices
Selected Press Releases, Announcements
WHO African Region AFRO
:: Africa records over 500 000 COVID-19 cases 08 July 2020
Brazzaville/Cairo – COVID-19 infections in Africa today surpassed 500 000, and there is concern as a growing number of countries are experiencing a sharp rise in cases. So far, in less than five months, the virus has claimed 11 959 lives, overtaking the 11 308 lives lost in the world’s worst Ebola outbreak in West Africa between 2014 and 2016.
Cases have more than doubled in 22 countries in the region over the past month. Nearly two-thirds of countries are experiencing community transmission. Algeria, Egypt, Ghana, Nigeria and South Africa account for about 71% of COVID-19 cases. South Africa alone accounts for 43% of the continent’s total cases…
:: Burkina Faso resumes polio vaccination campaigns under strict COVID-19 prevention measures 06 July 2020
Brazzaville – Burkina Faso today concluded a four-day mass polio immunization campaign, vaccinating 174 304 children under five years of age in two districts of the country’s Centre-East region while observing COVID-19 infection prevention and control measures.
The campaign is the first to be conducted since the government suspended all mass immunization on 27 March due to the COVID-19 pandemic to comply with the physical distancing guidelines to curb transmission of the virus.
As immunization campaigns resume, World Health Organization (WHO) teams at both regional and country offices have developed guidance for countries and frontline workers to ensure their safety and that of the children and their families…

WHO Region of the Americas PAHO
:: PAHO Director calls for protection of health workers in face of the advancing COVID19 pandemic in the region of the Americas (04/07/2020)
:: Amid COVID-19 pandemic, new WHO report urges greater investments in the nursing workforce (04/07/2020)

WHO South-East Asia Region SEARO
:: Maldives, Sri Lanka eliminate measles and rubella, ahead of 2023 target 8 July 2020 News release

WHO European Region EURO
:: New WHO study shows how Ireland can reduce health-related financial hardship and unmet need by delivering universal access to health care 08-07-2020
:: WHO/Europe expert team reaches Turkmenistan to support the country’s COVID-19 response 07-07-2020

WHO Eastern Mediterranean Region EMRO
:: COVID-19 presents opportunities for greater collaboration on the SDGS, says WHO’s Regional Director 8 July 2020
:: WHO delivers essential COVID-19 supplies to Afghanistan 5 July 2020

WHO Western Pacific Region
No new digest content identified

CDC/ACIP [to 11 July 2020]

CDC/ACIP [to 11 July 2020]
http://www.cdc.gov/media/index.html
https://www.cdc.gov/vaccines/acip/index.html

MMWR News Synopsis Friday, July 10, 2020
Increases in Health-Related Workplace Absenteeism among Workers in Essential Critical Infrastructure Occupations during the COVID-19 Pandemic—United States, March–April 2020

Provision of Pediatric Immunization Services During the COVID-19 Pandemic: An Assessment of Capacity Among Pediatric Immunization Providers Participating in the Vaccines for Children Program — United States, May 2020

Race/Ethnicity, Underlying Medical Conditions, Homelessness, and Hospitalization Status of Adult Patients with COVID-19 at an Urban Safety-Net Medical Center — Boston, Massachusetts, 2020

Initial and Repeated Point Prevalence Surveys to Inform SARS-CoV-2 Infection Prevention in 26 Skilled Nursing Facilities — Detroit, Michigan, March–May 2020 (Early release July 1, 2020)

Update: COVID-19 Among Workers in Meat and Poultry Processing Facilities ― United States, April–May 2020 (Early release July 7, 2020)

African Union Commission launches Consortium for COVID-19 Vaccine Clinical Trials

Africa CDC [to 11 July 2020]
http://www.africacdc.org/
News
African Union Commission launches Consortium for COVID-19 Vaccine Clinical Trials
9 July 2020
The African Union Commission has launched a new initiative, the Africa Centres for Disease Control and Prevention (Africa CDC) Consortium for COVID-19 Vaccine Clinical Trial (CONCVACT).
CONCVACT is an outcome of the virtual conference on Africa’s Leadership Role in COVID-19 Vaccine Development and Access held on 24-25 June 2020. The conference was hosted by Africa CDC and presided over by the Chairperson of the African Union, H.E. President Cyril Ramaphosa and the Chairperson of the African Union Commission, H.E. Moussa Faki Mahamat.
“Success in developing and providing access to a safe vaccine requires an innovative and collaborative approach, with significant local manufacturing in Africa. We need to support the contribution of African scientists and healthcare professionals. We need to act with urgency,” said H.E. President Cyril Ramaphosa…
CONCVACT aims to secure more than 10 late stage vaccine clinical trials as early as possible on the continent by bringing together global vaccine developers and funders, as well as African organizations that facilitate clinical trials. The goal is to ensure that sufficient data is generated on the safety and efficacy of the most promising vaccine candidates for the African population so they can be confidently rolled out in Africa once vaccines are approved.
CONCVACT will focus on dismantling the most critical barriers to clinical trials by:
[1] establishing partnerships with leading vaccine developers to host select late-stage trial sites in Africa;
[2] identifying countries and regions where opportunities to conduct trials are most promising (e.g. availability of strong local trial sponsors, good clinical practice investigators, access to granular epidemiologic data, support from regulatory bodies);
[3] setting up an independent review board to provide guidance, assistance and oversight to clinical trials (e.g. regulatory, ethics, safety, etc.);
[4] engaging with African and global media and key opinion leaders on the continent to increase public awareness of the need and importance of hosting well-regulated clinical trials in Africa;
[5] providing objective, fact-based scientific guidance for interpreting the results of clinical trial data;
[6] engaging global donors that are interested in investing in scaling-up vaccine distribution in Africa to raise sufficient funds to support the trials…

China CDC

China CDC
http://www.chinacdc.cn/en/
No new digest content identified.

 

National Health Commission of the People’s Republic of China
http://en.nhc.gov.cn/
News
July 11: Daily briefing on novel coronavirus cases in China
On July 10, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 2 new cases of confirmed infections and no new cases of suspected infections.

Beijing reports zero new virus cases 2 days in a row
2020-07-09

WHO to send experts to China for cooperation on COVID-19 origin-tracing: FM spokesperson
2020-07-09

Over 11 mln in Beijing given COVID-19 tests
2020-07-07

Announcements

Announcements

 

Paul G. Allen Frontiers Group [to 11 July 2020]
https://alleninstitute.org/what-we-do/frontiers-group/news-press/
News
Old age changes the way blood accesses the brain

July 7, 2020
A new study in mice shows that contrary to longstanding dogma, blood proteins easily cross into the brain, but transport machinery breaks down with age

Press Release
The Leukemia & Lymphoma Society, The Mark Foundation for Cancer Research and The Paul G. Allen Frontiers Group Partner to Award $6.75M in New Grants to Drive the Next Wave of Novel Cancer Therapies
July 1, 2020

 

BARDA – U.S. Department of HHS [to 11 July 2020]
https://www.phe.gov/about/barda/Pages/default.aspx
July 9, 2020: BARDA and JPEO-CBRND establish partnership with Retractable Technologies, Inc. to expand the capacity to manufacture needles and syringes in the US

July 9, 2020: BARDA and JPEO-CBRND establish partnership with Becton Dickinson to expand domestic manufacturing capacity for needles and syringes

July 7, 2020: HHS, DOD Collaborate with Novavax to Produce Millions of COVID-19 Investigational Vaccine Doses in Commercial-Scale Manufacturing Demonstration Projects
The U.S. Department of Health and Human Services (HHS) and Department of Defense (DoD) today jointly announced a $1.6 billion agreement with Novavax, Inc. of Gaithersburg, Maryland, to demonstrate commercial-scale manufacturing of the company’s COVID-19 investigational vaccine. By funding this manufacturing effort, the federal government will own the 100 million doses of investigational vaccine expected to result from the demonstration projects.
The doses would become available for use in clinical trials or, if the U.S. Food and Drug Administration (FDA) grants Emergency Use Authorization (EUA) or licenses (approves) the investigational vaccine, the federal government could distribute the doses as part of a COVID-19 vaccination campaign.
FDA can issue EUAs to facilitate the availability of an unapproved product only after several statutory requirements are met. For investigational vaccines being developed to prevent COVID-19, an assessment will be made on a case-by-case basis depending on the clinical trial data and the total scientific evidence available about the vaccine candidate. Additional analysis is required for FDA to license a vaccine…

July 7, 2020: HHS, DOD Collaborate with Regeneron on Large-Scale Manufacturing Demonstration Project of COVID-19 Investigational Therapeutic Treatment

 

BMGF – Gates Foundation [to 11 July 2020]
http://www.gatesfoundation.org/Media-Center/Press-Releases
No new digest content identified.

 

Bill & Melinda Gates Medical Research Institute [to 11 July 2020]
https://www.gatesmri.org/
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
No new digest content identified.

 

CARB-X [to 11 July 2020]
https://carb-x.org/
CARB-X is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.
07.07.2020  |
CARB-X is funding Spanish biotech Vaxdyn to develop a new vaccine to prevent infections that cause life-threatening pneumonia and other deadly infections
CARB-X is awarding Vaxdyn, based in Seville, Spain, up to US$892,000, plus an additional $6.36 million if certain project milestones are met, to develop a new vaccine to prevent life-threatening drug-resistant infections, including pneumonia.

 

CEPI – Coalition for Epidemic Preparedness Innovations [to 11 July 2020]
http://cepi.net/
Latest News
Nominations open for experts to join COVAX group advising on COVID-19 vaccine candidates
COVAX, one of the four ACT Accelerator Pillars, is setting up an Independent Product Group to advise on COVID-19 vaccine candidates. Deadline for nominations to join Friday 17 July.
COVID-19 09 Jul 2020

CEPI expands partnership with Clover Biopharmaceuticals to rapidly advance development and manufacture of COVID-19 vaccine candidate
Funding will support clinical development in parallel with scale-up of manufacturing capacity to potentially produce hundreds of millions of doses per year.
COVID-19 07 Jul 2020

 

EDCTP [to 11 July 2020]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
Latest news
09 July 2020
Today! – Online information session on Career Development Fellowships call

 

Emory Vaccine Center [to 11 July 2020]
http://www.vaccines.emory.edu/
No new digest content identified.

 

European Medicines Agency [to 11 July 2020]
http://www.ema.europa.eu/ema/
News & Press Releases
Press release: International regulators align positions on phase 3 COVID-19 vaccine trials
Last updated: 09/07/2020
Medicines regulatory authorities from around the world have published a report  today highlighting the outcomes of the second workshop on COVID-19 vaccine development that was convened under the umbrella of the International Coalition of Medicines Regulatory Authorities (ICMRA).
The report describes the regulatory positions agreed by the meeting participants on two key topics:
:: Data needed from laboratory, animal and human studies to allow initiation of phase 3 clinical trials for a COVID-19 vaccine; and
:: Considerations for study design for phase 3 clinical trials.
Phase 3 is the last phase of testing of a vaccine before it can be submitted to a regulatory authority for evaluation and possible approval. The main focus of phase 3 trials is to demonstrate efficacy and safety of the vaccine.
The meeting participants stressed the need for large phase 3 clinical trials that enroll many thousands of people, including those with underlying medical conditions, to generate relevant data for the key target populations.
There was also broad agreement that clinical studies should be designed with stringent success criteria that would allow a convincing demonstration of the efficacy of COVID-19 vaccines. However, whether a vaccine would be considered as acceptable for approval is assessed case-by-case on the basis of all available data on its safety and efficacy

 

 

Press release: International regulators provide guiding principles for COVID-19 clinical trials
Last updated: 01/07/2020
EMA has endorsed a joint statement on prioritisation of COVID-19 clinical trials published by the International Coalition of Medicines Regulatory Authorities (ICMRA). Medicines regulators from around the world have jointly developed this statement to step up global collaboration to facilitate and expedite the development and evaluation of therapeutics, diagnostics and vaccines against COVID-19.
“As the COVID-19 pandemic continues to evolve in many countries, we have seen unprecedented global collaboration and a surge in research and development of potential medicines and vaccines against coronavirus disease around the world,” said Guido Rasi, Chair of ICMRA and EMA’s Executive Director. “We, as regulators, support the trials that are providing robust and reliable results required for regulatory decision-making, and evidence that can be used across the globe for all patients affected by COVID-19.”…

 

European Vaccine Initiative [to 11 July 2020]
http://www.euvaccine.eu/
Latest News
No new digest content identified.

 

FDA [to 11 July 2020]
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/default.htm
Press Announcements
July 10, 2020 – Coronavirus (COVID-19) Update: Daily Roundup July 10, 2020

July 10, 2020 – Coronavirus (COVID-19) Update: FDA prepares for resumption of domestic inspections with new risk assessment system

July 9, 2020 – Coronavirus (COVID-19) Update: Daily Roundup July 9, 2020

July 8, 2020 – Coronavirus (COVID-19) Update: Daily Roundup July 8, 2020

July 6, 2020 – Coronavirus (COVID-19) Update: Daily Roundup July 6, 2020

July 6, 2020 – Coronavirus (COVID-19) Update: FDA Issued Emergency Use Authorization for Point of Care Antigen Test

 

Fondation Merieux [to 11 July 2020]
http://www.fondation-merieux.org/
News, Events
No new digest content identified.

 

Gavi [to 11 July 2020]
https://www.gavi.org/
News releases
No new digest content identified.

 

GHIT Fund [to 11 July 2020]
https://www.ghitfund.org/newsroom/press
GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that No new digest content identified.

 

Global Fund [to 11 July 2020]
https://www.theglobalfund.org/en/news/
No new digest content identified.

 

Hilleman Laboratories [to 11 July 2020]
http://www.hillemanlabs.org/
No new digest content identified.

 

Human Vaccines Project [to 11 July 2020]
http://www.humanvaccinesproject.org/media/press-releases/
HVP COVID Report
COVID-19 Vaccines: Proceed at Warp Speed or Festina Lente?
By John P. Moore, PhD.
Professor of Microbiology and Immunology
Weill Cornell Medicine. New York

 

IAVI [to 11 July 2020]
https://www.iavi.org/newsroom
July 9, 2020
IAVI and Scripps Research Join Efforts with NIH to Expedite Development of Globally Accessible and Affordable HIV Antibody Combination Products
Antibody injections could offer HIV protection that would be of special value to women and girls in low-income countries
NEW YORK – JULY 9, 2020 – Today during the global conference AIDS 2020: Virtual, IAVI, a scientific research organization dedicated to addressing urgent unmet health needs including HIV and tuberculosis, announced an innovative collaboration with Scripps Research and the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH). These leading scientific organizations are pooling their HIV broadly neutralizing antibody (bnAb) assets and expertise to develop a combination product specifically designed to be produced at scale to provide prompt, affordable, and sustainable global access, should bnAbs be shown to be efficacious for HIV prevention and possibly for treatment.
Through this collaboration, scientists from the IAVI Neutralizing Antibody Center (NAC), Scripps Research, and NIH will work together to expedite the development of a combination product, including their most potent and broadly neutralizing antibodies, that is designed to protect against the wide genetic diversity of circulating HIV strains…

 

 

International Coalition of Medicines Regulatory Authorities [ICMRA]
http://www.icmra.info/drupal/en/news
Selected Statements, Press Releases, Research
No new digest content identified.

 

 

International Generic and Biosimilar Medicines Association [IGBA]
https://www.igbamedicines.org/
News
No new digest content identified.

 

 

IFFIm
http://www.iffim.org/
Announcements
IFFIm issues NOK 2 billion in Vaccine Bonds for COVID-19 vaccine development
07 Jul 2020
IFFIm has issued NOK 2 billion in Vaccine Bonds to accelerate the availability of financing for urgent COVID-19 vaccine research and development by the Coalition for Epidemic Preparedness Innovations

 

IFRC [to 11 July 2020]
http://media.ifrc.org/ifrc/news/press-releases/
Selected Press Releases, Announcements
No new digest content identified.

 

IVAC [to 11 July 2020]
https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html
Updates
New VIEW-Hub Look
July 2020
VIEW-hub is IVAC’s publicly accessible interactive platform to visualize real-time information on vaccine use, product type, coverage levels, impact assessments, and disease burden estimates. It has a new look now.

 

IVI [to 11 July 2020]
http://www.ivi.int/
Selected IVI News & Announcements
IVI welcomes the First Lady of South Korea to a solidarity event for global health and vaccine equity
July 8, 2020

 

JEE Alliance [to 11 July 2020]
https://www.jeealliance.org/
Selected News and Events
No new digest content identified.

 

MSF/Médecins Sans Frontières [to 11 July 2020]
http://www.msf.org/
Latest [Selected Announcements]
Coronavirus COVID-19 pandemic
As COVID-19 spreads, fear drives people away from hospitals in Yemen
Press Release 9 Jul 2020

Malawi
Tackling a silent woman-killer in Malawi
Voices from the Field 9 Jul 2020

El Salvador
People are dying at home amid collapsing health system in El Salvador
Project Update 9 Jul 2020

Cambodia
Innovation needed to respond to COVID-19 in Cambodia
Project Update 7 Jul 2020

Access to medicines
Governments must scale up better TB treatment as J&J drops crucial drug pr…
Press Release 6 Jul 2020

Iraq
2019 MSF Iraq annual report
Report 6 Jul 2020

 

National Vaccine Program Office – U.S. HHS [to 11 July 2020]
https://www.hhs.gov/vaccines/about/index.html
NVAC 2020 Meetings
September 23-24, 2020 Meeting (Virtual)

 

NIH [to 11 July 2020]
http://www.nih.gov/news-events/news-releases
Selected News Releases
NIH launches clinical trials network to test COVID-19 vaccines and other prevention tools
July 8, 2020 — Network website features secure method for volunteering for studies.
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has established a new clinical trials network that aims to enroll thousands of volunteers in large-scale clinical trials testing a variety of investigational vaccines and monoclonal antibodies intended to protect people from COVID-19.
The COVID-19 Prevention Trials Network (COVPN) was established by merging four existing NIAID-funded clinical trials networks: the HIV Vaccine Trials Network (HVTN), based in Seattle; the HIV Prevention Trials Network (HPTN), based in Durham, N.C.; the Infectious Diseases Clinical Research Consortium (IDCRC), based in Atlanta; and the AIDS Clinical Trials Group, based in Los Angeles. Those individual networks will continue to perform clinical trials for HIV vaccine and prevention and other infectious diseases in addition to their new COVID roles…

 

PATH [to 11 July 2020]
https://www.path.org/media-center/
Selected Announcements
PATH recognized at AIDS 2020 for research on promoting community-led HIV services in Vietnam
July 8, 2020 by PATH
Yesterday, at the 23rd International AIDS Conference (AIDS 2020), PATH’s Bao Ngoc Vu, MD, received one of the International AIDS Society/Merck Sharpe & Dohme Prizes for Operational and Implementation Research in Differentiated Service Delivery in recognition of outstanding research in differentiated service delivery…

PATH receives new five-year contract from USAID for malaria vaccine research and development
Seattle, WA, July 7, 2020 – PATH is proud to announce a new five-year, $27 million partnership with the United States Agency for International Development (USAID) to develop a next-generation malaria vaccine. The project will focus on identifying and advancing vaccines with greatest potential to benefit those at highest risk of disease and death from malaria. Despite impressive declines in malaria deaths and cases over the past two decades, progress has stalled, and malaria continues to kill over 400,000 people each year; young African children remain most vulnerable. New tools are urgently needed to reduce disease and death attributable to malaria, and to accelerate elimination and eventual eradication…

 

Sabin Vaccine Institute [to 11 July 2020]
http://www.sabin.org/updates/pressreleases
Statements and Press Releases
No new digest content identified.

 

UNAIDS [to 11 July 2020]
http://www.unaids.org/en
Selected Press Releases/Reports/Statements
10 July 2020
Ensuring access to quality, safe, and non-discriminatory services for HIV key populations and migrants in the context of the COVID-19 pandemic

10 July 2020
Survey shows that the COVID-19 pandemic increases vulnerability of LGBTI people

10 July 2020
UNAIDS and the wider United Nations system supporting the COVID-19 response in Nigeria

9 July 2020
Next global AIDS strategy: be part of making history

8 July 2020
Setting the next generation of goals for the global AIDS response

8 July 2020
Support for Uzbek mothers living with HIV

 

UNICEF [to 11 July 2020]
https://www.unicef.org/media/press-releases
Selected Press releases/Announcements
Press release
08/07/2020
Marley family to ‘reimagine’ Bob Marley’s One Love in support of UNICEF
Re-recording of iconic anthem will support UNICEF’s Reimagine campaign, a global fundraising appeal to respond, recover and reimagine a post-COVID-19 world fit for children

Press release
08/07/2020
UN agencies welcome latest relocations of unaccompanied children from Greece, call for further action and solidarity

 

Unitaid [to 11 July 2020]
https://unitaid.org/
Featured News
09 July 2020 | Press releases
FIND and Unitaid launch call for expression of interest to accelerate availability and manufacturing scale-up of rapid diagnostic tests for COVID-19
:: Call aims to fill major diagnostic gaps in the detection of active SARS-CoV-2 infection for patient management and contact tracing purposes in decentralized settings, most critically needed in low- and middle-income countries (LMICs)
:: Innovators, developers and manufacturers of rapid diagnostic tests and in vitro diagnostics, and LMIC-based diagnostic stakeholders, are invited to submit proposals
:: Launch of this EOI is the latest milestone for the Access to COVID-19 Tools (ACT) Accelerator Diagnostics Pillar, co-convened by FIND and The Global Fund to Fight AIDS, Tuberculosis and Malaria

 

Vaccination Acceptance Research Network (VARN) [to 11 July 2020]
https://vaccineacceptance.org/news.html#header1-2r
Announcements
No new digest content identified.

 

Vaccine Confidence Project [to 11 July 2020]
http://www.vaccineconfidence.org/
Latest News & Archive
Report
The Public’s Role in COVID-19 Vaccination: Planning Recommendations Informed by Design Thinking and the Social, Behavioral, and Communication Sciences
Working Group on Readying Populations for COVID-19 Vaccine
Johns Hopkins Center for Health Security
July 2020
This report considers human factors in relation to future vaccines against the novel coronavirus (SARS-CoV-2), drawing on insights from design thinking and the social, behavioral, and communication sciences. It provides recommendations—directed to both US policymakers and practitioners, as well as nontraditional partners new to public health’s mission of vaccination—on how to advance public understanding of, access to, and acceptance of vaccines that protect against COVID-19.

 

Vaccine Education Center – Children’s Hospital of Philadelphia [to 11 July 2020]
http://www.chop.edu/centers-programs/vaccine-education-center
No new digest content identified.

 

Wellcome Trust [to 11 July 2020]
https://wellcome.ac.uk/news
No new digest content identified.

 

The Wistar Institute [to 11 July 2020]
https://www.wistar.org/news/press-releases
Press Released
The Wistar Institute Appoints Chengyu Liang, M.D., Ph.D., as Professor in Its Cancer Center 
PHILADELPHIA — (July 6, 2020) — The Wistar Institute, an international biomedical research leader in cancer, immunology and infectious diseases, announces the appointment of Chengyu Liang, M.D., Ph.D., as professor in the Molecular & Cellular Oncogenesis Program of The Wistar Institute Cancer Center.
The Liang laboratory is focused on understanding the mechanisms that regulate fundamental cellular processes such as autophagy, cell death, DNA damage repair, and membrane trafficking in the context of cancer and infectious disease.

 

WFPHA: World Federation of Public Health Associations [to 11 July 2020]
https://www.wfpha.org/
Latest News
No new digest content identified.

 

World Organisation for Animal Health (OIE) [to 11 July 2020]
https://www.oie.int/en/for-the-media/press-releases/2020/
Press Releases
No new digest content identified.

 

 

::::::

 

ARM [Alliance for Regenerative Medicine] [to 11 July 2020]
https://alliancerm.org/press-releases/
Press Releases
Alliance for Regenerative Medicine Responds to EU Pharmaceutical Roadmap
WASHINGTON, DC and BRUSSELS, BELGIUM – July 7, 2020
Leading international advocacy group calls for effective regulation, clinical trial support, and value-based reimbursement that benefits patient access to ATMPs

 

BIO [to 11 July 2020]
https://www.bio.org/press-releases
Press Releases
Biopharmaceutical Leaders Announce New Effort to Tackle Superbugs, Spur Development of New Antibiotics
July 9, 2020
Today more than 20 leading biopharmaceutical companies announced the creation of an estimated $1 billion fund to help support the pipeline for new antibiotic treatments. The AMR Action Fund was launched as the threat of antimicrobial resistance, or…

 

DCVMN – Developing Country Vaccine Manufacturers Network [to 11 July 2020]
http://www.dcvmn.org/
News; Upcoming events
WEBINAR: Vaccine Innovation Priority Strategy (VIPS): Update
16 July 2020

WEBINAR: Defining the concept on fair pricing for medicines
21 July 2020

 

IFPMA [to 11 July 2020]
http://www.ifpma.org/resources/news-releases/
Selected Press Releases, Statements, Publications
New AMR Action Fund steps in to save collapsing antibiotic pipeline with pharmaceutical industry investment
09 July 2020
:: New AMR Action Fund steps in to save collapsing antibiotic pipeline with pharmaceutical industry investment of US$1 billion
:: Partnership aims to bring 2 to 4 new antibiotics to patients by the end of the decade and facilitate needed long-term policy solutions
9 July 2020, Geneva — Today, more than 20 leading biopharmaceutical companies announced the launch of the AMR Action Fund [www.AMRactionfund.com], a ground-breaking partnership that aims to bring 2-4 new antibiotics to patients by 2030. These treatments are urgently needed to address the rapid rise of antibiotic-resistant infections – also called antimicrobial resistance, or AMR.  The companies have raised so far nearly US$1 billion new funding to support clinical research of innovative new antibiotics that are addressing the most resistant bacteria and life-threatening infections. Through the AMR Action Fund, pharmaceutical companies will join forces with philanthropies, development banks, and multilateral organizations to strengthen and accelerate antibiotic development. The Fund will focus on urgent public health needs.  It will provide much needed financial resources, as well as important technical support to help biotech companies bring novel antibiotics to patients.
The AMR Action Fund, an initiative of the international body representing the R&D pharmaceutical industry (International Federation of Pharmaceutical Manufacturers & Associations, IFPMA), was announced at simultaneous virtual launch events in Berlin, Germany, and Washington, D.C., USA, with a third event in Tokyo, Japan taking place on July 10.
AMR is a looming global crisis that has the potential to dwarf COVID-19 in terms of deaths and economic costs. While tragically the death toll of COVID-19 continues to rise, each year 700,000 people are dying from AMR. In some of the most alarming scenarios, it is estimated that by 2050 AMR could claim as many as 10 million lives per year.
“Unlike COVID-19, AMR is a predictable and preventable crisis. We must act together to rebuild the pipeline and ensure that the most promising and innovative antibiotics make it from the lab to patients,” said Thomas Cueni, Director General of the IFPMA, one of the organizers of the new fund. He adds: “The AMR Action Fund is one of the largest and most ambitious collaborative initiatives ever undertaken by the pharmaceutical industry to respond to a global public health threat”…

Joint Guidance on Virtual International Medical Congresses Impacted by COVID-19
02 July 2020

IFPMA Global Code Comparison Report 2020
02 July 2020

 

ICBA – International Council of Biotechnology Associations [to 11 July 2020]
https://internationalbiotech.org/
News
No new digest content identified.

 

PhRMA [to 11 July 2020]
http://www.phrma.org/
Selected Press Releases, Statements
New initiative to bridge the gap on antimicrobial innovation
Stephen J. Ubl   |     July 9, 2020
oday, more than 20 leading biopharmaceutical companies are launching the AMR Action Fund, a ground-breaking partnership to invest nearly $1 billion to ensure a robust and diverse pipeline of new medicines to treat drug-resistant infections…

Journal Watch

Journal Watch
Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focu-s on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.
If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

Mobile Health Technology for Enhancing the COVID-19 Response in Africa: A Potential Game Changer?

American Journal of Tropical Medicine and Hygiene
Volume 103, Issue 1, July 2020
http://www.ajtmh.org/content/journals/14761645/103/1

 

Editorial
Mobile Health Technology for Enhancing the COVID-19 Response in Africa: A Potential Game Changer?
Jean B. Nachega, Rory Leisegang, Oscar Kallay, Edward J. Mills, Alimuddin Zumla and Richard T. Lester
Pages: 3–5
https://doi.org/10.4269/ajtmh.20-0506

Mass Drug Administration and Worms Experience in Africa: Envisage Repurposing Ivermectin for SARS-COV-2

American Journal of Tropical Medicine and Hygiene
Volume 103, Issue 1, July 2020
http://www.ajtmh.org/content/journals/14761645/103/1

 

Stories from the Field
Mass Drug Administration and Worms Experience in Africa: Envisage Repurposing Ivermectin for SARS-COV-2
Claire Njeri Wamae
Pages: 10–11
https://doi.org/10.4269/ajtmh.20-0295

Recommendations for the COVID-19 Response at the National Level Based on Lessons Learned from the Ebola Virus Disease Outbreak in the Democratic Republic of the Congo

American Journal of Tropical Medicine and Hygiene
Volume 103, Issue 1, July 2020
http://www.ajtmh.org/content/journals/14761645/103/1

 

Perspective Piece
Recommendations for the COVID-19 Response at the National Level Based on Lessons Learned from the Ebola Virus Disease Outbreak in the Democratic Republic of the Congo
Linda Meta Mobula, Hadia Samaha, Michel Yao, Abdou Salam Gueye, Boubacar Diallo, Chantal Umutoni, Julienne Anoko, Jean-Pierre Lokonga, Luigi Minikulu, Mathias Mossoko, Emanuele Bruni, Simone Carter, Thibaut Jombart, Ibrahima Soce Fall and Steve Ahuka-Mundeke
Pages: 12–17
https://doi.org/10.4269/ajtmh.20-0256

The impact of healthcare worker influenza vaccination on nosocomial influenza in a tertiary hospital: an ecological study

BMC Health Services Research
http://www.biomedcentral.com/bmchealthservres/content
(Accessed 11 July 2020)

 

The impact of healthcare worker influenza vaccination on nosocomial influenza in a tertiary hospital: an ecological study
To protect hospitalized patients, who are more susceptible to complications of influenza, seasonal influenza vaccination of healthcare workers (HCW) has been recommended internationally. However, its effective…
Authors: Wycliffe Enli Wei, Stephanie Fook-Chong, Wen Kai Chen, Maciej Piotr Chlebicki and Wee Hoe Gan
Citation: BMC Health Services Research 2020 20:636
Content type: Research article
Published on: 10 July 2020

Paradoxical long-term impact of maternal influenza infection on neonates and infants

BMC Infectious Diseases
http://www.biomedcentral.com/bmcinfectdis/content
(Accessed 11 July 2020)

 

Paradoxical long-term impact of maternal influenza infection on neonates and infants
Pregnant women are at high risk of influenza-related morbidity and mortality. In addition, maternal influenza infection may lead to adverse birth outcomes. However, there is insufficient data on long-term impa…
Authors: Joon Young Song, Keon Vin Park, Sung Won Han, Min Joo Choi, Ji Yun Noh, Hee Jin Cheong, Woo Joo Kim, Min-Jeong Oh and Geum Joon Cho
Citation: BMC Infectious Diseases 2020 20:502
Content type: Research article
Published on: 11 July 2020

Estimating the nationwide transmission risk of measles in US schools and impacts of vaccination and supplemental infection control strategies

BMC Infectious Diseases
http://www.biomedcentral.com/bmcinfectdis/content
(Accessed 11 July 2020)

 

Estimating the nationwide transmission risk of measles in US schools and impacts of vaccination and supplemental infection control strategies
The spread of airborne infectious diseases such as measles is a critical public health concern. The U.S. was certified measles-free in 2000, but the number of measles cases has increased in recent years breaki…
Authors: Parham Azimi, Zahra Keshavarz, Jose Guillermo Cedeno Cedeno Laurent and Joseph G. Allen
Citation: BMC Infectious Diseases 2020 20:497
Content type: Research article
Published on: 11 July 2020

Measuring vaccine effectiveness against persistent HPV infections: a comparison of different statistical approaches

BMC Infectious Diseases
http://www.biomedcentral.com/bmcinfectdis/content
(Accessed 11 July 2020)

 

Measuring vaccine effectiveness against persistent HPV infections: a comparison of different statistical approaches
Persistent high-risk human papillomavirus (HPV) infection is endorsed by the World Health Organization as an intermediate endpoint for evaluating HPV vaccine effectiveness/efficacy. There are different approac…
Authors: R. Donken, J. Hoes, M. J. Knol, G. S. Ogilvie, S. Dobson, A. J. King, J. Singer, P. J. Woestenberg, J. A. Bogaards, C. J. L. M. Meijer and H. E. de Melker
Citation: BMC Infectious Diseases 2020 20:482
Content type: Research article
Published on: 8 July 2020

Inequalities in measles immunization coverage in Ethiopia: a cross-sectional analysis of demographic and health surveys 2000–2016

BMC Infectious Diseases
http://www.biomedcentral.com/bmcinfectdis/content
(Accessed 11 July 2020)

 

Inequalities in measles immunization coverage in Ethiopia: a cross-sectional analysis of demographic and health surveys 2000–2016
Ethiopia has low measles immunization coverage and little is known about the disparities surrounding what coverage is provided. This study assessed disparities in measles immunization and its change over time …
Authors: Gebretsadik Shibre, Betregiorgis Zegeye, Dina Idriss-Wheeler and Sanni Yaya
Citation: BMC Infectious Diseases 2020 20:481
Content type: Research article
Published on: 7 July 2020

Making researchers responsible: attributions of responsibility and ambiguous notions of culture in research codes of conduct

BMC Medical Ethics
http://www.biomedcentral.com/bmcmedethics/content
(Accessed 11 July 2020)

 

Making researchers responsible: attributions of responsibility and ambiguous notions of culture in research codes of conduct
Research codes of conduct offer guidance to researchers with respect to which values should be realized in research practices, how these values are to be realized, and what the respective responsibilities of the individual and the institution are in this. However, the question of how the responsibilities are to be divided between the individual and the institution has hitherto received little attention. We therefore performed an analysis of research codes of conduct to investigate how responsibilities are positioned as individual or institutional, and how the boundary between the two is drawn.
Authors: Govert Valkenburg, Guus Dix, Joeri Tijdink and Sarah de Rijcke
Citation: BMC Medical Ethics 2020 21:56
Content type: Research article
Published on: 7 July 2020

Short- and long-term impact of vaccination against cytomegalovirus: a modeling study

BMC Medicine
http://www.biomedcentral.com/bmcmed/content
(Accessed 11 July 2020)

 

Short- and long-term impact of vaccination against cytomegalovirus: a modeling study
Infection with cytomegalovirus (CMV) is highly prevalent worldwide and can cause severe disease in immunocompromised persons and congenitally infected infants. The disease burden caused by congenital CMV infec…
Authors: Ganna Rozhnova, Mirjam E. Kretzschmar, Fiona van der Klis, Debbie van Baarle, Marjolein Korndewal, Ann C. Vossen and Michiel van Boven
Citation: BMC Medicine 2020 18:174
Content type: Research Article
Published on: 2 July 2020

Unvaccinated children as community parasites in National Qualitative Study from Turkey

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 11 July 2020)

 

Unvaccinated children as community parasites in National Qualitative Study from Turkey
This national qualitative study explores (1) the experiences, observations, and opinions of health care workers (HCWs) about beliefs, socioeconomic, cultural, and environmental characteristics of parents refusing vaccination and (2) regional differences in the identified risk factors; (3) recommended solutions to improve vaccine acceptance in each of 12 regions in Turkey.
Authors: Sıddıka Songül Yalçin, Ayça Gelgeç Bakacak and Osman Topaç
Citation: BMC Public Health 2020 20:1087
Content type: Research article
Published on: 11 July 2020

Effect of vaccine reminder and tracker bracelets on routine childhood immunization coverage and timeliness in urban Pakistan (2017-18): a randomized controlled trial

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 11 July 2020)

 

Effect of vaccine reminder and tracker bracelets on routine childhood immunization coverage and timeliness in urban Pakistan (2017-18): a randomized controlled trial
Inability to track children’s vaccination history coupled with parents’ lack of awareness of vaccination due dates compounds the problem of low immunization coverage and timeliness in developing countries. We …
Authors: Danya Arif Siddiqi, Rozina Feroz Ali, Mehr Munir, Mubarak Taighoon Shah, Aamir Javed Khan and Subhash Chandir
Citation: BMC Public Health 2020 20:1086
Content type: Research article
Published on: 11 July 2020

Acceptability of a hypothetical preventative HIV vaccine among people who use drugs in Vancouver, Canada

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 11 July 2020)

 

Acceptability of a hypothetical preventative HIV vaccine among people who use drugs in Vancouver, Canada
As research on HIV vaccines continues to advance, studies exploring the feasibility of this intervention are necessary to inform uptake and dissemination strategies with key populations, including people who u…
Authors: Taylor Fleming, Jenna Valleriani, Cara Ng, Lisa Maher, Will Small and Ryan McNeil
Citation: BMC Public Health 2020 20:1081
Content type: Research article
Published on: 9 July 2020

Reflections on 25 Years of Health and Human Rights: History, Context, and the Need for Strategic Action

Health and Human Rights
Volume 22, Issue 1, June 2020
https://www.hhrjournal.org/volume-22-issue-1-june-2020/

 

Special Section: Mental Health and Human Rights
Viewpoints
Reflections on 25 Years of Health and Human Rights: History, Context, and the Need for Strategic Action
Sofia Gruskin
…The crisis of the moment calls for us to be strategic, not just reactive, and to be able to count on one another whatever our past and present differences. Taking a long view, the stakes are just too high. As a first step we need to support publication of efforts in all domains—research, programming, service delivery, and activism—that can help to ensure the health and human rights of all people, and however “sensitive” the issue, do not slide off the table simply because it’s a complicated political moment. We risk losing not only the gains made so far, but attention and support for the very many tough issues at the crux of health and human rights work. We need more than ever to draw attention to all that is happening to undermine health and rights, and collectively determine how to directly take this on wherever we work. This is not simply a matter of academic concern. It tangibly matters for the health and lives of people around the globe. Twenty-five years since its inception, the importance of the Journal, and the space it provides to keep critical issues on the table in academic, policy, and programmatic discussions, has never been greater..

COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)
Volume 16, Issue 6, 2020
http://www.tandfonline.com/toc/khvi20/current

 

Review
COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics
Kuldeep Dhama , Khan Sharun , Ruchi Tiwari , Maryam Dadar , Yashpal Singh Malik , Karam Pal Singh & Wanpen Chaicumpa
Pages: 1232-1238
Published online: 18 Mar 2020

Polio vaccination campaign in Pakistan: a step towards eradication or still a challenge in hand?

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)
Volume 16, Issue 6, 2020
http://www.tandfonline.com/toc/khvi20/current

 

Article Commentary
Polio vaccination campaign in Pakistan: a step towards eradication or still a challenge in hand?
Tauseef Ahmad , Muhammad Khan , Taha Hussein Musa & Jin Hui
Pages: 1444-1445
Published online: 25 Mar 2020

Armed conflict, a neglected determinant of childhood vaccination: some children are left behind

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)
Volume 16, Issue 6, 2020
http://www.tandfonline.com/toc/khvi20/current

 

Review
Armed conflict, a neglected determinant of childhood vaccination: some children are left behind
Ngo Valery Ngo , Ngambouk Vitalis Pemunta , Nyenkuna Elisabeth Muluh , Miranda Adedze , Nduma Basil & Simon Agwale
Pages: 1454-1463
Published online: 06 Dec 2019

Strategies supporting the prevention and control of neglected tropical diseases during and beyond the COVID-19 pandemic

Infectious Diseases of Poverty
http://www.idpjournal.com/content
[Accessed 11 July 2020]

 

Strategies supporting the prevention and control of neglected tropical diseases during and beyond the COVID-19 pandemic
Emerging and re-emerging zoonotic diseases represent a public health challenge of international concern. They include a large group of neglected tropical diseases (NTDs), many of which are of zoonotic nature. …
Authors: John P. Ehrenberg, Xiao-Nong Zhou, Gilberto Fontes, Eliana M. M. Rocha, Marcel Tanner and Jürg Utzinger
Citation: Infectious Diseases of Poverty 2020 9:86
Content type: Commentary
Published on: 10 July 2020

Ensuring Access to Medications in the US During the COVID-19 Pandemic

JAMA
July 7, 2020, Vol 324, No. 1, Pages 7-110
https://jamanetwork.com/journals/jama/currentissue

 

Viewpoint
Ensuring Access to Medications in the US During the COVID-19 Pandemic
G. Caleb Alexander, MD, MS; Dima M. Qato, PharmD, MPH, PhD
free access has active quiz
JAMA. 2020;324(1):31-32. doi:10.1001/jama.2020.6016
This Viewpoint proposes strategies to ensure adequate supply and distribution of medication in the US during and beyond the coronavirus pandemic, including development and funding of a national essential medicines supply, allocation strategies to prevent stockpiling, and funding of home delivery services to ensure adequate access for lower income and underserved populations.

Ensuring Access to Medications in the US During the COVID-19 Pandemic

JAMA
July 7, 2020, Vol 324, No. 1, Pages 7-110
https://jamanetwork.com/journals/jama/currentissue

 

Viewpoint
Ensuring Access to Medications in the US During the COVID-19 Pandemic
G. Caleb Alexander, MD, MS; Dima M. Qato, PharmD, MPH, PhD
free access has active quiz
JAMA. 2020;324(1):31-32. doi:10.1001/jama.2020.6016
This Viewpoint proposes strategies to ensure adequate supply and distribution of medication in the US during and beyond the coronavirus pandemic, including development and funding of a national essential medicines supply, allocation strategies to prevent stockpiling, and funding of home delivery services to ensure adequate access for lower income and underserved populations.

Conducting Clinical Research During the COVID-19 Pandemic – Protecting Scientific Integrity

JAMA
July 7, 2020, Vol 324, No. 1, Pages 7-110
https://jamanetwork.com/journals/jama/currentissue

 

Viewpoint
Conducting Clinical Research During the COVID-19 Pandemic – Protecting Scientific Integrity
Thomas R. Fleming, PhD; Dominic Labriola, PhD; Janet Wittes, PhD
free access
JAMA. 2020;324(1):33-34. doi:10.1001/jama.2020.9286
This Viewpoint discusses procedures to ensure the safety of RCT participants without sacrificing the validity of trials conducted during the COVID-19 pandemic, including home-based test drug administration and outcome measurement, prespecifying stopping rules for pandemic-related interruptions, and stratifying analyses by pandemic-imposed differences in study conduct.

Patterns of Influenza Vaccination and Vaccine Effectiveness Among Young US Children Who Receive Outpatient Care for Acute Respiratory Tract Illness

JAMA Pediatrics
July 2020, Vol 174, No. 7, Pages 633-736
http://archpedi.jamanetwork.com/issue.aspx

 

Original Investigation
Patterns of Influenza Vaccination and Vaccine Effectiveness Among Young US Children Who Receive Outpatient Care for Acute Respiratory Tract Illness
Jessie R. Chung, MPH; Brendan Flannery, PhD; Manjusha Gaglani, MBBS; et al.
JAMA Pediatr. 2020;174(7):705-713. doi:10.1001/jamapediatrics.2020.0372
This case-control study compares vaccine effectiveness against medically attended, laboratory-confirmed influenza in infants and children who received 1 vs 2 doses of influenza vaccine.

The Case for Why Africa Should Host COVID-19 Candidate Vaccine Trials

Journal of Infectious Diseases
Volume 222, Issue 3, 1 August 2020
https://academic.oup.com/jid/issue/222/3

 

COVID PERSPECTIVES
The Case for Why Africa Should Host COVID-19 Candidate Vaccine Trials
Jerome Amir Singh
The Journal of Infectious Diseases, Volume 222, Issue 3, 1 August 2020, Pages 351–355, https://doi.org/10.1093/infdis/jiaa303
African sites should be central to COVID-19 vaccine trial site mapping. Such an approach is in the interests of public health, scientifically responsible, and realizes key ethics values.

Paying Participants in COVID-19 Trials

Journal of Infectious Diseases
Volume 222, Issue 3, 1 August 2020
https://academic.oup.com/jid/issue/222/3

 

COVID-2019
Paying Participants in COVID-19 Trials
Emily A Largent, Holly Fernandez Lynch
The Journal of Infectious Diseases, Volume 222, Issue 3, 1 August 2020, Pages 356–361, https://doi.org/10.1093/infdis/jiaa284
Payment for research participation is ethically contentious even under ideal circumstances, and concerns about offering payment are likely to be heightened in the current pandemic. This article describes the role of payment in COVID-19 trials and highlights ethical considerations.

Focus on CRISPR tools and therapies

Nature Biotechnology
Volume 38 Issue 7, July 2020
https://www.nature.com/nbt/volumes/38/issues/7

 

Focus on CRISPR tools and therapies
CRISPR-based genome editing has become a mainstay of experimental biology and is now maturing into a tool for therapeutic applications. Constant progress is being made in designing ever more sophisticated protein machines to catalyze desired changes with high efficiency and specificity, and in the methods to deliver the macromolecules involved to the tissues and cells. Many of the more recent advances have not entered clinical development yet, but will ultimately help therapeutic genome editing fulfill its full potential.

The delivery challenge: fulfilling the promise of therapeutic genome editing

Nature Biotechnology
Volume 38 Issue 7, July 2020
https://www.nature.com/nbt/volumes/38/issues/7

 

Focus on CRISPR tools and therapies
Review Article | 29 June 2020
The delivery challenge: fulfilling the promise of therapeutic genome editing
As CRISPR therapies move into clinical testing, David Schaffer and colleagues review a raft of different delivery technologies being road tested to address cargo capacity limitations, maximize potency, minimize off-target effects and avoid immunogenicity.
Joost van Haasteren, Jie Li[…] & David V. Schaffer

Privacy challenges and research opportunities for genomic data sharing

Nature Genetics
Volume 52 Issue 7, July 2020
https://www.nature.com/ng/volumes/52/issues/7

 

Review Article | 29 June 2020
Privacy challenges and research opportunities for genomic data sharing
This review discusses major privacy threats relevant to collection and analysis of genomic data in the context of direct-to-consumer applications and provides suggestions for improving the design of privacy-protecting approaches.
Luca Bonomi, Yingxiang Huang & Lucila Ohno-Machado

Hepatitis B screening and vaccination status of healthcare providers in Wakiso district, Uganda

PLoS One
http://www.plosone.org/
[Accessed 11 July 2020]

 

Hepatitis B screening and vaccination status of healthcare providers in Wakiso district, Uganda
Tonny Ssekamatte, Trasias Mukama, Simon P. S. Kibira, Rawlance Ndejjo, Justine Nnakate Bukenya, Zirimala Paul Alex Kimoga, Samuel Etajak, Rebecca Nuwematsiko, Esther Buregyeya, John C. Ssempebwa, John Bosco Isunju, Richard Kibirango Mugambe, Aisha Nalugya, Solomon Tsebeni Wafula, Joan Nankya Mutyoba
Research Article | published 09 Jul 2020 PLOS ONE
https://doi.org/10.1371/journal.pone.0235470